^
Association details:
| Biomarker: | KRAS mutation + PD-L1 negative |
|---|---|
| Cancer: | Lung Non-Squamous Non-Small Cell Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + bemcentinib (BGB324) (AXL inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1440P - Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
Published date:
10/16/2023
Excerpt:
BGBC008 is a ph2 open-label, single-arm study of bem+pembro in 2L NS NSCLC...The mOS and mPFS for the PD-L1- (n=6) and PD-L1+ (n=11) KRASMT pts were 18 vs 11.4 mths (p=0.017) and 17.3 vs 6.1 mths (p=0.09), respectively.
Trial ID:
